OC
MCID: OVR042
MIFTS: 88

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 57 12 73 20 43 58 72 36 29 54 6 42 3 15
Ovarian Carcinoma 12 20 43 54 6 15 17 70
Ovarian Neoplasm 12 17 70
Malignant Neoplasm of Ovary 70 32
Epithelial Ovarian Cancer 72 70
Neoplasm of Ovary 29 6
Ovarian Neoplasms 54 44
Ovarian Cancers 6 15
Primary Malignant Neoplasm of Ovary 70
Malignant Neoplasm of the Ovary 43
Malignant Tumor of the Ovary 43
Malignant Tumour of Ovary 12
Ovarian Cancer, Somatic 57
Malignant Ovarian Tumor 12
Ovarian Malignant Tumor 58
Primary Ovarian Cancer 12
Cancer of the Ovary 43
Tumor of the Ovary 12
Ovarian Carcinomas 15
Cancer, Ovarian 39
Ovary Neoplasm 12
Oc 72

Characteristics:

Orphanet epidemiological data:

58
ovarian cancer
Prevalence: 1-5/10000 (Europe);

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
somatic mutation


HPO:

31
ovarian cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:2394 DOID:4001
OMIM® 57 167000
KEGG 36 H00027
ICD9CM 34 183.0
MeSH 44 D010051
NCIt 50 C4984 C7431
ICD10 32 C56
UMLS via Orphanet 71 C1140680
Orphanet 58 ORPHA213500
UMLS 70 C0029925 C0677886 C0919267 more

Summaries for Ovarian Cancer

MedlinePlus Genetics : 43 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.The most common form of ovarian cancer begins in epithelial cells, which are the cells that line the surfaces and cavities of the body. These cancers can arise in the epithelial cells on the surface of the ovary. However, researchers suggest that many or even most ovarian cancers begin in epithelial cells on the fringes (fimbriae) at the end of one of the fallopian tubes, and the cancerous cells migrate to the ovary.Cancer can also begin in epithelial cells that form the lining of the abdomen (the peritoneum). This form of cancer, called primary peritoneal cancer, resembles epithelial ovarian cancer in its origin, symptoms, progression, and treatment. Primary peritoneal cancer often spreads to the ovaries. It can also occur even if the ovaries have been removed. Because cancers that begin in the ovaries, fallopian tubes, and peritoneum are so similar and spread easily from one of these structures to the others, they are often difficult to distinguish. These cancers are so closely related that they are generally considered collectively by experts.In about 10 percent of cases, ovarian cancer develops not in epithelial cells but in germ cells, which are precursors to egg cells, or in hormone-producing ovarian cells called granulosa cells.In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.In some cases, cancerous tumors can invade surrounding tissue and spread to other parts of the body. If ovarian cancer spreads, cancerous tumors most often appear in the abdominal cavity or on the surfaces of nearby organs such as the bladder or colon. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.Some ovarian cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases.Because it is often diagnosed at a late stage, ovarian cancer can be difficult to treat; it leads to the deaths of about 14,000 women annually in the United States, more than any other gynecological cancer. However, when it is diagnosed and treated early, the 5-year survival rate is high.

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and breast cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are MicroRNAs in cancer and Innate Immune System. The drugs Iron and Ferrous fumarate have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and prostate, and related phenotypes are breast carcinoma and abnormality of metabolism/homeostasis

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

GARD : 20 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome ) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

OMIM® : 57 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000) (Updated 05-Apr-2021)

MedlinePlus : 42 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. When ovarian cancer is found in its early stages, treatment works best. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you. Symptoms may be caused by something other than cancer, but the only way to know is to see your doctor, nurse, or other health care professional. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome, raise ovarian cancer risk. Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, occurring in about 70% of ovarian cancer cases.

KEGG : 36 Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.

Novus Biologicals : 55 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 72 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 73 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Related Diseases for Ovarian Cancer

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1368)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 35.0 TP53 RAD51L3-RFFL RAD51D RAD51C PTEN MSH6
2 breast cancer 34.7 TP53 RAD51L3-RFFL RAD51D RAD51C PTEN PIK3CA
3 lynch syndrome 34.3 TP53 RAD51L3-RFFL RAD51D RAD51C PTEN PIK3CA
4 breast-ovarian cancer, familial 1 34.2 RAD51C MSH6 MSH2 BRCA2 BRCA1
5 pancreatic cancer 34.2 TP53 PTEN PIK3CA MSH2 MAP3K1 KRAS
6 endometrial cancer 33.8 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
7 adenocarcinoma 33.8 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
8 ovary adenocarcinoma 33.6 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
9 fallopian tube carcinoma 33.6 TP53 RAD51D RAD51C PTEN ERBB2 BRCA2
10 ovary epithelial cancer 33.6 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
11 serous cystadenocarcinoma 33.5 TP53 PTEN PIK3CA KRAS ERBB2 BRCA2
12 ovarian disease 33.5 TP53 PTEN ERBB2 CTNNB1 BRCA2 BRCA1
13 hereditary site-specific ovarian cancer syndrome 33.3 RAD51L3-RFFL RAD51D RAD51C BRCA2 BRCA1
14 familial ovarian cancer 33.3 RAD51C BRIP1 BRCA2 BRCA1
15 breast-ovarian cancer, familial 4 33.1 RAD51L3-RFFL RAD51D
16 ovarian clear cell carcinoma 33.1 TP53 PTEN PIK3CA KRAS
17 prostate cancer 33.1 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
18 fanconi anemia, complementation group a 33.0 TP53 RAD51D RAD51C PTEN PRKN MSH6
19 li-fraumeni syndrome 33.0 TP53 RAD51D RAD51C PTEN MSH6 MSH2
20 cystadenocarcinoma 33.0 TP53 PIK3CA ERBB2 BRCA1 BRAF AKT1
21 papillary serous adenocarcinoma 33.0 TP53 KRAS BRCA2 BRCA1
22 familiar ovarian carcinoma 32.9 PIK3CA BRCA1
23 ovarian cystadenocarcinoma 32.8 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
24 skin carcinoma 32.8 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
25 melanoma 32.8 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
26 peripheral nervous system disease 32.8 TP53 PTEN PRKN ERBB2 CTNNB1 AKT1
27 bladder cancer 32.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
28 adenoma 32.7 TP53 PIK3CA MSH6 MSH2 KRAS CTNNB1
29 gastric cancer 32.7 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
30 leukemia, acute myeloid 32.7 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
31 ovarian serous cystadenocarcinoma 32.6 TP53 PIK3CA KRAS ERBB2 BRAF AKT1
32 bilateral breast cancer 32.6 TP53 PTEN PIK3CA MSH6 ERBB2 CDH1
33 lung cancer susceptibility 3 32.5 TP53 PRKN PIK3CA KRAS ERBB2 CTNNB1
34 in situ carcinoma 32.5 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
35 primary peritoneal carcinoma 32.4 TP53 ERBB2 BRCA2 BRCA1
36 ovarian serous carcinoma 32.4 TP53 KRAS CDH1 BRCA1
37 atypical teratoid rhabdoid tumor 32.4 TP53 CTNNB1 BRCA2
38 uterine corpus cancer 32.4 TP53 PTEN PIK3CA MSH6 MSH2 KRAS
39 cervical cancer 32.4 TP53 PTEN PIK3CA ERBB2 CTNNB1 AKT1
40 teratoma 32.4 TP53 PTEN KRAS CTNNB1 CDH1 AKT1
41 carcinosarcoma 32.3 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
42 cowden syndrome 32.3 TP53 RAD51D RAD51C PTEN PIK3CA MSH6
43 glioblastoma 32.3 TP53 PTEN PIK3CA MSH2 ERBB2 BRCA2
44 hereditary nonpolyposis colon cancer 32.2 MSH6 MSH2 BRCA2 BRCA1
45 gastric cancer, hereditary diffuse 32.2 TP53 RAD51D RAD51C PTEN MSH6 MSH2
46 squamous cell carcinoma 32.2 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
47 papillary adenocarcinoma 32.2 TP53 ERBB2 CDH1 BRCA2 BRCA1
48 esophageal cancer 32.2 TP53 PTEN PIK3CA KRAS ERBB2 CTNNB1
49 wilms tumor 1 32.2 TP53 KRAS ERBB2 CTNNB1 CDH1 BRCA2
50 sporadic breast cancer 32.2 TP53 RAD51C PTEN ERBB2 BRCA2 BRCA1

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer

Symptoms & Phenotypes for Ovarian Cancer

Human phenotypes related to Ovarian Cancer:

31
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 31 HP:0003002
2 abnormality of metabolism/homeostasis 31 HP:0001939
3 dysgerminoma 31 HP:0100621
4 ovarian papillary adenocarcinoma 31 HP:0006774

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Neoplasia:
dysgerminoma
ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM®:

167000 (Updated 05-Apr-2021)

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.73 KRAS PIK3CA BRAF
2 Decreased viability GR00055-A-2 10.73 KRAS PIK3CA BRAF
3 Decreased viability GR00055-A-3 10.73 KRAS
4 Decreased viability GR00106-A-0 10.73 KRAS
5 Decreased viability GR00107-A-1 10.73 MAP3K1
6 Decreased viability GR00221-A-1 10.73 AKT1 KRAS PIK3CA CDH1
7 Decreased viability GR00221-A-2 10.73 AKT1 BRCA1 KRAS MAP3K1 PIK3CA
8 Decreased viability GR00221-A-3 10.73 AKT1 BRCA1 MAP3K1
9 Decreased viability GR00221-A-4 10.73 AKT1 PIK3CA BRAF
10 Decreased viability GR00249-S 10.73 AKT1 BRAF
11 Decreased viability GR00301-A 10.73 BRCA1 KRAS BRAF CDH1 MSH2
12 Decreased viability GR00381-A-1 10.73 KRAS BRAF
13 Decreased viability GR00402-S-2 10.73 PIK3CA CDH1
14 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 10.16 PRKN RAD51D TP53
15 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 10.16 AKT1 BRAF BRCA1 BRIP1 PTEN RAD51D
16 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10.16 BRAF BRCA1 BRCA2 BRIP1 RAD51D TP53
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.1 AKT1 BRCA1 BRCA2 PTEN
18 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.1 AKT1 BRCA1 BRCA2 PRKN PTEN TP53
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.1 BRCA1 BRCA2 RAD51D TP53 MSH2 MSH6
20 Decreased cell migration GR00055-A-1 9.58 AKT1
21 Decreased cell migration GR00055-A-3 9.58 BRAF PIK3CA
22 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 BRIP1
23 Synthetic lethal with cisplatin GR00101-A-1 9.33 BRCA1 BRCA2 BRIP1
24 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.1 BRAF BRCA1 BRCA2 MAP3K1 MSH2 RAD51D

MGI Mouse Phenotypes related to Ovarian Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
2 homeostasis/metabolism MP:0005376 10.47 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
3 cardiovascular system MP:0005385 10.44 AKT1 BRAF BRCA1 CDH1 CTNNB1 ERBB2
4 growth/size/body region MP:0005378 10.42 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
5 behavior/neurological MP:0005386 10.41 AKT1 BRAF BRCA1 BRCA2 BRIP1 CTNNB1
6 integument MP:0010771 10.41 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
7 mortality/aging MP:0010768 10.41 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
8 embryo MP:0005380 10.38 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
9 endocrine/exocrine gland MP:0005379 10.37 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
10 immune system MP:0005387 10.34 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
11 neoplasm MP:0002006 10.31 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
12 nervous system MP:0003631 10.28 AKT1 BRAF BRCA1 BRCA2 BRIP1 CTNNB1
13 digestive/alimentary MP:0005381 10.27 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
14 muscle MP:0005369 10.2 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
15 limbs/digits/tail MP:0005371 10.19 BRAF BRCA1 BRCA2 BRIP1 CTNNB1 ERBB2
16 normal MP:0002873 10.06 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
17 reproductive system MP:0005389 9.97 AKT1 BRAF BRCA1 BRCA2 BRIP1 CDH1
18 no phenotypic analysis MP:0003012 9.91 CDH1 CTNNB1 KRAS OPCML PIK3CA PRKN
19 pigmentation MP:0001186 9.86 BRAF BRCA1 BRIP1 CTNNB1 KRAS MAP3K1
20 respiratory system MP:0005388 9.61 AKT1 BRAF BRCA1 CTNNB1 ERBB2 KRAS
21 skeleton MP:0005390 9.4 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2

Drugs & Therapeutics for Ovarian Cancer

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 548)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925 29936
2
Ferrous fumarate Approved Phase 4 141-01-5
3
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
4 Protein Kinase Inhibitors Phase 4
5
Apatinib Phase 4 811803-05-1
6
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
7
Hydralazine Approved Phase 3 86-54-4 3637
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
10
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
11
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
12
Busulfan Approved, Investigational Phase 3 55-98-1 2478
13
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
14
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
15
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
16
tannic acid Approved Phase 3 1401-55-4
17
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
18
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
19
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
20
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
21
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
22
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
23
Calcium polycarbophil Approved Phase 3 126040-58-2
24
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
25
Selenious acid Approved, Investigational Phase 3 7783-00-8
26
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
27
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
28
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
29
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
30
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
31
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
32
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
33
Ifosfamide Approved Phase 3 3778-73-2 3690
34
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
35
Adenosine Approved, Investigational Phase 3 58-61-7 60961
36
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
37
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
38
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
39
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
40
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
41
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
42
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
43
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
44
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
45
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
46
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
47
carbamide peroxide Approved Phase 3 124-43-6
48
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
50 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8

Interventional clinical trials:

(show top 50) (show all 2010)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Unknown status NCT03858166 Phase 4 PEG-rhG-CSF
3 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
4 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
5 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
6 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
7 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
8 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
9 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
10 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
11 Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer Recruiting NCT03164980 Phase 4 Trabectidin (Yondelis)
12 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
13 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
14 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
15 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
16 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Recruiting NCT04352439 Phase 4 Aspirin
17 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
18 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
19 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
20 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
21 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
22 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
23 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
24 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
25 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
26 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
27 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
28 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
29 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
30 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
31 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
32 A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Unknown status NCT01837251 Phase 3 Carboplatin;PLD
33 Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers Unknown status NCT03717610 Phase 3
34 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
35 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
36 Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. Unknown status NCT03162276 Phase 3
37 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
38 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
39 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
40 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
41 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
42 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
43 Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line Completed NCT02490488 Phase 2, Phase 3 Masitinib;Gemcitabine;Placebo
44 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
45 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
46 A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
47 Impact of Exercise on Ovarian Cancer Prognosis Completed NCT02107066 Phase 3
48 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Completed NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery
49 Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy Completed NCT00426257 Phase 3
50 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Altretamine
Carboplatin
Chlorambucil
Chromic phosphate P32
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
docetaxel
doxorubicin hydrochloride liposome
hydroxyurea
Ifosfamide
Leuprolide
Leuprolide Acetate
Melphalan
Melphalan hydrochloride
Paclitaxel
Topotecan
Topotecan Hydrochloride
Uracil Mustard
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 29 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 29

Anatomical Context for Ovarian Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

19
Ovary

MalaCards organs/tissues related to Ovarian Cancer:

40
Breast, Ovary, Prostate, T Cells, Lung, Lymph Node, Endothelial

Publications for Ovarian Cancer

Articles related to Ovarian Cancer:

(show top 50) (show all 42723)
# Title Authors PMID Year
1
Mutations in BRIP1 confer high risk of ovarian cancer. 6 57 61
21964575 2011
2
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. 57 6 61
12819783 2003
3
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 6 57
12719539 2003
4
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. 61 57 54
19635727 2010
5
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. 6 54 61
19358724 2009
6
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 6 61 54
19018267 2008
7
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. 54 57 61
15619626 2005
8
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. 61 57 54
11179017 2001
9
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. 54 61 57
10577927 1999
10
DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. 57 61 54
9620555 1998
11
BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. 61 6
29368626 2018
12
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. 61 6
28423363 2017
13
Inherited Mutations in Women With Ovarian Carcinoma. 61 6
26720728 2016
14
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. 6 61
26315354 2015
15
Whole-genome characterization of chemoresistant ovarian cancer. 57 61
26017449 2015
16
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. 61 6
21990120 2012
17
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. 61 6
22006311 2011
18
Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 6 61
21975775 2011
19
RAD51C is a susceptibility gene for ovarian cancer. 6 61
21616938 2011
20
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. 6 61
21683865 2011
21
Integrated genomic analyses of ovarian carcinoma. 61 57
21720365 2011
22
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. 47 54 61
20461750 2010
23
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 57 61
19304784 2009
24
Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. 57 61
19270026 2009
25
Dicer, Drosha, and outcomes in patients with ovarian cancer. 61 57
19092150 2008
26
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. 54 6
18628483 2008
27
Histologic subtypes of ovarian carcinoma: an overview. 57 61
18317227 2008
28
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. 61 54 47
18199536 2008
29
Classification of ovarian cancer: a genomic analysis. 61 57
18546616 2008
30
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. 57 61
18026186 2008
31
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 6 54
17611497 2007
32
Mutation of the PIK3CA gene in ovarian and breast cancer. 6 54
15520168 2004
33
Alterations in the common fragile site gene Parkin in ovarian and other cancers. 54 57
14614460 2003
34
Identification of prognostic factors in advanced epithelial ovarian carcinoma. 57 61
11520151 2001
35
Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. 57 61
9826475 1998
36
Is hereditary site-specific ovarian cancer a distinct genetic condition? 61 57
9450858 1998
37
A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. 57 61
8603384 1996
38
Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. 57 61
8640783 1996
39
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. 57 54
7942844 1994
40
A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. 61 6
8052619 1994
41
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. 61 57
8314147 1994
42
Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. 57 61
1394208 1992
43
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. 57 61
2250917 1990
44
An oncogenic chromosome 8-9 gene fusion isolated following transfection of human ovarian carcinoma cell line DNA. 57 61
1973829 1990
45
Familial ovarian carcinoma. 57 61
4320145 1970
46
Low FOXJ2 expression is associated with unfavorable postoperative prognosis of patients with epithelial ovarian cancer. 42 61
33725831 2021
47
Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors. 61 42
33663040 2021
48
A novel biomarker, MRPS12 functions as a potential oncogene in ovarian cancer and is a promising prognostic candidate. 42 61
33663122 2021
49
Germline-Activating RRAS2 Mutations Cause Noonan Syndrome. 6
31130285 2019
50
Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. 6
31130282 2019